Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma approval

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

Celgene building

NICE rejects Celgene’s Vidaza for leukaemia

Final draft guidance cites ‘high degree of uncertainty’ over clinical efficacy

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

Celgene building

Celgene forms real-time, real-world trial partnership

Will collaborate with TriNetX, using its electronic medical records network

- PMLiVE

Celgene launches ‘edu-tainment’ psoriasis awareness initiative

Millefeuille film seeks to highlight everyday burden of the disease

Bristol-Myers Squibb (BMS) building

BMS gets two new cancer approvals in Europe

Empliciti, and Opdivo and Yervoy inhibitor combination get the green light

- PMLiVE

Celgene creates art gallery to highlight impact of psoriasis

Life's an Itch gallery will be used at meetings and medical conferences

Celgene building

Celgene: Patient voice often underrepresented in pricing debates

Dr Jackie Fouse says in the interests of transparency patients should be more involved

Celgene building

Wales backs NHS use of Abraxane despite NICE rejection

Overrules UK decision and will maintain access to Celgene’s pancreatic cancer drug

- PMLiVE

Amgen’s roll-out of myeloma drug Kyprolis reaches UK

Company hopes to gain NICE approval later this year

- PMLiVE

Celgene uses ‘video views’ map in arthritis awareness drive

Be Counted! campaign highlights US views of its short films

- PMLiVE

Celgene makes changes to its senior leadership team

Bob Hugin, Mark Alles, Jacqualyn Fouse and Scott Smith take on new roles

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links